Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

The Latest Breaking News from Eli Lilly

Big pharma firms have paused nearly £2bn in UK investments this year

Government’s plans in disarray before Trump talks as MSD, Eli Lilly and AstraZeneca moves prompt job fears

The Guardian - UK

Pharma Giant Eli Lilly (LLY) Could Still Be a Screaming Deal—Here’s the Statistical Evidence

Pharma Giant Eli Lilly (LLY) Could Still Be a Screaming Deal—Here’s the Statistical Evidence

Although healthcare juggernaut Eli Lilly has struggled for momentum this year, the latest unusual options activity for LLY stock could point to potential upside.

AstraZeneca Puts Cambridge Expansion On Ice Adding Pressure On Starmer Ahead Of Trump Visit

AstraZeneca Puts Cambridge Expansion On Ice Adding Pressure On Starmer Ahead Of Trump Visit

The U.K.-based AstraZeneca Plc (NASDAQ:AZN) paused a planned 200 million pounds ($271.26 million) investment in its Cambridge research site.

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Urgent warning over illegal weight loss jabs ‘not approved for humans’ offered for sale on TikTok

Exclusive: TikTok sellers purporting to sell the ‘Triple G’ of weight loss jabs have had their accounts pulled after The Independent exposed them to the social media giant

The Independent UK

Eli Lilly Loses Appeal Over Medicaid Drug Pricing Fraud Case

A federal appeals court has upheld a $183.7 million judgment against Eli Lilly and Co. (NYSE:LLY), rejecting the drugmaker's attempt to overturn a whistleblower lawsuit that accused it of defrauding Medicaid.

Wegovy And Zepbound Cost Effective But They Could Break Drug Budgets

The Institute for Clinical and Economic Review (ICER) on Tuesday released a Draft Evidence Report assessing the comparative clinical effectiveness and value of Novo Nordisk A/S’ (NYSE:NVO) semaglutide (Wegovy) and Eli Lilly and Co.’s (NYSE:LLY) tirzepatide (Zepbound) for obesity management.

Novo Nordisk to cut 9,000 jobs as Eli Lilly competition intensifies

The pharmaceutical giant will axe over 11% of its global workforce as rival Eli Lilly gathers market share in the obesity drug market.

inkl

Read news from The Economist, FT, and more,
with one subscription

Novo Nordisk To Cut 9,000 Jobs As Competition From Eli Lilly Heats Up: Analyst Calls Move 'Tough, Natural...Very Necessary'

Novo Nordisk To Cut 9,000 Jobs As Competition From Eli Lilly Heats Up: Analyst Calls Move 'Tough, Natural...Very Necessary'

Novo Nordisk (NYSE:NVO) has announced a significant restructuring plan that will see the company cut 9,000 jobs, representing 11.5% of its workforce. The decision comes as the pharmaceutical giant faces mounting pressure from U.S. competitor Eli Lilly (NYSE:LLY).

Wegovy maker Novo Nordisk to cut 9,000 jobs amid increased competition

Wegovy maker Novo Nordisk to cut 9,000 jobs amid increased competition

Danish manufacturer of weight-loss and diabetes drugs under pressure from US rival Eli Lilly

The Guardian - UK

Defiance Has A New ETF For High-Stakes Pharma Traders

Defiance Has A New ETF For High-Stakes Pharma Traders

Defiance ETFs launched its newest leveraged product on Sept. 3, the Defiance Daily Target 2X Short LLY ETF (NASDAQ:LLYZ). The new fund is designed for traders seeking to short pharmaceutical giant Eli Lilly and Co (NYSE:LLY).

Eli Lilly Meshes AI With Drug Research, Touts $1B Worth Of Research Data

Eli Lilly Meshes AI With Drug Research, Touts $1B Worth Of Research Data

Eli Lilly and Co. (NYSE:LLY) on Tuesday launched Lilly TuneLab, an artificial intelligence and machine learning (AI/ML) platform that provides biotech companies access to drug discovery models trained on years of Lilly’s research data.

Eli Lilly's Jaypirca Surpasses Chemoimmunotherapy For Untreated Blood Cancer Patients

Eli Lilly's Jaypirca Surpasses Chemoimmunotherapy For Untreated Blood Cancer Patients

Eli Lilly and Co (NYSE:LLY) on Monday shared topline results from the Phase 3 BRUIN CLL-313 clinical trial of Jaypirca (pirtobrutinib), a non-covalent (reversible) Bruton tyrosine kinase (BTK) inhibitor, versus chemoimmunotherapy (bendamustine plus rituximab), in treatment-naïve patients with chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL) without 17p deletions.

Ozempic Is The New Botox And Big Pharma Is Printing Billions

Ozempic Is The New Botox And Big Pharma Is Printing Billions

Ozempic and Zepbound have morphed from diabetes treatment into a cultural phenomenon, helping Novo Nordisk A/S (NYSE:NVO) and Eli Lilly And Co (NYSE:LLY) achieve a combined market cap topping $900 billion. Celebrities flaunt it, Silicon Valley elites swear by it, and analysts predict the GLP-1 market could surpass $150 billion…

UK ‘will be one of the first countries’ to get new weight-loss pill

UK ‘will be one of the first countries’ to get new weight-loss pill

The Independent UK

Get all your
news in one place.

100's of premium titles.
One news app.

The Independent UK

New weight-loss pill could reach UK by next year, says Mounjaro boss

Eli Lilly’s new pill could offer an easier path to weight loss for needle-averse patients

The Independent UK

MP loses eight stone on Mounjaro but fears price hike will stop others benefiting

The MP for Neath and Swansea East fears the drug’s price rise will exclude others from using Mounjaro

The Independent UK

WHO has added GLP-1 drugs to the essential medicines list. Here’s what that means

GLP-1 drugs were initially developed for diabetes, but have become wildly popular weight-loss drugs too

The Guardian - UK

Thousands in England unable to access weight loss jabs via GP, figures reveal

Doctors say NHS rollout not fit for purpose with fewer than half of commissioning bodies prescribing Mounjaro

Get all your
news in one place.

100's of premium titles.
One news app.

FDA Breakthrough Status Awarded To Lilly-Merck Combo Drug For Advanced Non-Small Cell Lung Cancer

The U.S. Food and Drug Administration (FDA) on Thursday granted Breakthrough Therapy designation to Eli Lilly and Co.’s (NYSE:LLY) olomorasib, in combination with Merck Co. Inc.’s (NYSE:MRK) anti-PD-1 therapy Keytruda (pembrolizumab), for the first-line treatment of unresectable advanced or metastatic non-small cell lung cancer (NSCLC) with a KRAS G12C mutation…

The Independent UK

Scientists say there is no link between ‘microdosing’ weight-loss drugs and living longer

It is ‘too early’ to know whether small doses of weight-loss drugs can help you live longer, experts say

After Copycat Boom, China's Drugmakers Target Global Generics

China-based drugmakers that once fueled a surge of copycat weight-loss treatments in the U.S. are now pivoting to generics of Novo Nordisk‘s (NYSE:NVO) Wegovy and Eli Lilly's (NYSE:LLY) Zepbound as regulators tighten rules on compounded medicines.

Insiders Bought the Selloff in Eli Lilly. Should You Buy LLY Stock, Too?

What traders need to know about recent insider buying on LLY stock, and how to track insider moves using Barchart tools.

Novo Nordisk's Wegovy Outshines Eli Lilly's Tirzepatide In Reducing Risk Of Heart Attack, Stroke And Death

Novo Nordisk A/S (NYSE:NVO) on Sunday presented data from the STEER real-world study of evidence gathered from actual patient experiences at the European Society of Cardiology (ESC) Congress 2025.

Benzinga Bulls And Bears: Eli Lilly, Firefly, Marvell — And Trump Investment Hints Boost Defense Stocks

Benzinga examined the prospects for many investors' favorite stocks over the last week — here's a look at some of our top stories.

Evening Standard

What is the cheapest weight loss drug available in the UK?

We compared the prices of weight loss drugs licensed as prescription medication in the UK

1 … 7 8 9 10

People

186,373 stories

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Organisations

The Independent

inkl

Read news from The Economist, FT, and more,
with one subscription

Topics

Artificial Intelligence

Places

368,853 stories

137,969 stories

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.

Download on the AppStore

Get it on Google Play